UniQure Publishes Phase I/II Trial Results of AMT-060 Gene Therapy in Treating Hemophilia B

Pharmaceutical company and gene therapy leader, uniQure, published promising data from their current phase I/II trial testing out a gene therapy called AMT-060 in patients with serious cases of hemophilia B.

Researchers studied 10 adult patients, who tolerated the treatment well. The paper “Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B” appeared in Blood.

Read more about this on bioportfolio.com

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email